<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631588</url>
  </required_header>
  <id_info>
    <org_study_id>1940-102-008</org_study_id>
    <nct_id>NCT04631588</nct_id>
  </id_info>
  <brief_title>Intradermal (ID) BOTOX in the Treatment of Facial Fine Lines</brief_title>
  <official_title>Phase 1b Safety and Tolerability of Intradermal BOTOXÂ® (OnabotulinumtoxinA) Purified Neurotoxin Complex in Participants With Facial Fine Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess safety and tolerability of Intradermal (ID)&#xD;
      BOTOX in participants with facial fine lines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Actual">November 3, 2021</completion_date>
  <primary_completion_date type="Actual">November 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 1) to Final Visit (up to Day 97)</time_frame>
    <description>Unique number of participants who experience one or more treatment emergent adverse event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Potential Clinically Significant (PCS) changes in vital signs</measure>
    <time_frame>Baseline (Day 1) to Final Visit (up to Day 97)</time_frame>
    <description>Unique number of participants who experience one or more Potential Clinically Significant (PCS) change in vital signs from the Baseline visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Potential Clinically Significant (PCS) changes in physical exams</measure>
    <time_frame>Baseline (Day 1) to Final Visit (up to Day 97)</time_frame>
    <description>Unique number of participants who experience one or more Potential Clinically Significant (PCS) change in physical exams from the Baseline visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with injection site pain/discomfort.</measure>
    <time_frame>Baseline (Day 1)</time_frame>
    <description>Unique number of participants who experience injection site pain and/or discomfort at the injection site during administration of treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Facial Fine Lines</condition>
  <arm_group>
    <arm_group_label>Open Label BOTOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BOTOX at Baseline (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-Blind Randomized BOTOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BOTOX at Baseline (Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Blind Randomized Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Baseline (Day 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>Intradermal (ID) injection</description>
    <arm_group_label>Double-Blind Randomized BOTOX</arm_group_label>
    <arm_group_label>Open Label BOTOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal (ID) injection</description>
    <arm_group_label>Double Blind Randomized Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A female participant must be willing to minimize the risk of inducing pregnancy for&#xD;
             the duration of the clinical study (eg, for at least 90 days after receiving study&#xD;
             intervention).&#xD;
&#xD;
          -  Participant must have sufficient visual acuity without the use of eyeglasses (contact&#xD;
             lans use acceptable) to accurately assess their facial lines, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Participant must be in good health as determined by medical history, physical&#xD;
             examination, vital signs, and investigator's judgment, including no known active&#xD;
             COVID-19 infection.&#xD;
&#xD;
          -  Be nonsmoking and a nonuser of cannabis and nicotine-containing products, or have not&#xD;
             smoked or used cannabis or nicotine-containing products, including e-cigarettes,&#xD;
             within the previous 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known immunization or hypersensitivity to any botulinum toxin serotype.&#xD;
&#xD;
          -  Any medical condition that may put the participant at increased medical risk with&#xD;
             exposure to BOTOX including diagnosed myasthenia gravis, Eaton-Lambert syndrome,&#xD;
             amyotrophic lateral sclerosis, or any other condition that might interfere with&#xD;
             neuromuscular function.&#xD;
&#xD;
          -  Rosacea, skin infection, or any other skin disease or disorder that would represent a&#xD;
             safety concern and/or interfere with the ability to either administer treatment or&#xD;
             assess the treatment effect, as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin and Cancer Associates, LLP /ID# 225152</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137-3254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York /ID# 225153</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center /ID# 225151</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215-2885</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research /ID# 225154</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research /ID# 225155</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84101-1345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com.,To be considered as a site for current and future Allergan Clinical Trials, please register using the Investigator Databank link.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Facial Fine Lines,BOTOX,Onabotulinum Toxin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

